Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02320032 · ClinicalTrials.gov registry record · Phase 1
An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia
A Phase 1 study, sponsored by Alkermes.
- Completed
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
NCT02320032: Completed Phase 1 study, sponsored by Alkermes.
NCT02320032 is a Phase 1 study that has completed, run by Alkermes. The registered enrollment target is 140 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (133% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02320032, a Phase 1 study, has completed, sponsored by Alkermes.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of various doses and dosing intervals of aripiprazole lauroxil.
Primary Outcome
Area under the plasma-concentration time curve from time zero to the last quantifiable plasma concentration
Interventions
- DRUG Aripiprazole Lauroxil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2014-12 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
What the finished NCT02320032 record still lists
NCT02320032 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (133% higher).
The record links to 0 conditions, and to 1 intervention - of which Aripiprazole Lauroxil is the first listed.
NCT02320032 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02320032 about?
NCT02320032 is a clinical study titled "An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia". This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of various doses and dosing intervals of aripiprazole lauroxil.
What is the current status of trial NCT02320032?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2014-12. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02320032?
The interventions under investigation include: Aripiprazole Lauroxil (DRUG).
Who is sponsoring clinical trial NCT02320032?
This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02320032's enrollment target sits among peer trials
140 402nd of 2000 higher than 1,583 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia